Cargando…
HUS1 as a Potential Therapeutic Target in Urothelial Cancer
Platinum-based chemotherapy is the standard of care with concern to first-line systemic therapy for metastatic disease in urothelial cancer (UC). Resistance to chemotherapy despite an initial response is linked with the ability to remove platinum-based DNA adducts and to repair chemotherapy-induced...
Autores principales: | Lindner, Andrea Katharina, Furlan, Tobias, Orme, Jacob J., Tulchiner, Gennadi, Staudacher, Nina, D’Andrea, David, Culig, Zoran, Pichler, Renate |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031773/ https://www.ncbi.nlm.nih.gov/pubmed/35456300 http://dx.doi.org/10.3390/jcm11082208 |
Ejemplares similares
-
CMTM6 expression as a potential biomarker for immunotherapy in metastatic renal cell carcinoma
por: Tulchiner, Gennadi, et al.
Publicado: (2021) -
Lynch Syndrome: Its Impact on Urothelial Carcinoma
por: Lindner, Andrea Katharina, et al.
Publicado: (2021) -
The “COVID-19 Pandemic Gap” and Its Influence on Oncologic Outcomes of Bladder Cancer
por: Tulchiner, Gennadi, et al.
Publicado: (2021) -
Expression of ADAM Proteases in Bladder Cancer Patients with BCG Failure: A Pilot Study
por: Pichler, Renate, et al.
Publicado: (2021) -
Immune-related lichenoid mucocutaneous erosions during anti-PD-1 immunotherapy in metastatic renal cell carcinoma - A case report
por: Lindner, Andrea Katharina, et al.
Publicado: (2018)